Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Earth Science Tech (OTCMKTS:ETST – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Profitability
This table compares Xeris Biopharma and Earth Science Tech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -64.08% | -147.04% | -23.32% |
| Earth Science Tech | N/A | N/A | -38.82% |
Earnings and Valuation
This table compares Xeris Biopharma and Earth Science Tech’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $110.25 million | 3.12 | -$94.66 million | ($0.57) | -4.46 |
| Earth Science Tech | $50,000.00 | 314.25 | -$380,000.00 | N/A | N/A |
Analyst Ratings
This is a summary of current ratings for Xeris Biopharma and Earth Science Tech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 0 | 0 | 3 | 0 | 3.00 |
| Earth Science Tech | 0 | 0 | 0 | 0 | N/A |
Xeris Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 96.85%. Given Xeris Biopharma’s higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Earth Science Tech.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Earth Science Tech
Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Doral, Florida.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.jpg?v=20230511062707&h=45&w=95&zc=2){kind=logo}
